Apixaban in AVERROES points the way to excellent alternatives to warfarin

Afib patients taking apixaban had a 54% lower risk of stroke and systemic embolic events compared to those taking aspirin as reported in the AVERROES trial. With RE-LY fresh in our minds and in anticipation of the results of ROCKET-AF , ARISTOTLE, and ENGAGE-HF, the future looks bright for better alternatives to warfarin. What are your thoughts about this trial and its implications for clinical practice?

See:

AVERROES: Apixaban yields significant reductions in stroke, no increased bleeding

RE-LY: Oral antithrombin dabigatran outshines warfarin in atrial fib

RE-LY: Patient preference based on the data

Cite this: Apixaban in AVERROES points the way to excellent alternatives to warfarin - Medscape - Aug 31, 2010.